

# Tina Bagratuni

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1770502/publications.pdf>

Version: 2024-02-01

29  
papers

703  
citations

759055

12  
h-index

580701

25  
g-index

29  
all docs

29  
docs citations

29  
times ranked

1284  
citing authors

#	ARTICLE	IF	CITATIONS
1	Kinetics of anti-SARS-CoV-2 neutralizing antibodies development after BNT162b2 vaccination in patients with amyloidosis and the impact of therapy. American Journal of Hematology, 2022, 97, E27.	2.0	5
2	Determination of MYD88L265P mutation fraction in IgM monoclonal gammopathies. Blood Advances, 2022, 6, 189-199.	2.5	10
3	Third dose of the BNT162b2 vaccine results in very high levels of neutralizing antibodies against SARS-CoV-2: Results of a prospective study in 150 health professionals in Greece. American Journal of Hematology, 2022, 97, .	2.0	10
4	Persisting Endothelial Cell Activation and Hypercoagulability after COVID-19 Recovery”The Prospective Observational ROADMAP-Post COVID-19 Study. Hemato, 2022, 3, 111-121.	0.2	4
5	Patients With Autoimmune Thyroiditis Present Similar Immunological Response to COVID-19 BNT162b2 mRNA Vaccine With Healthy Subjects, While Vaccination May Affect Thyroid Function: A Clinical Study. Frontiers in Endocrinology, 2022, 13, 840668.	1.5	15
6	Plasma Metabolomic Alterations Induced by COVID-19 Vaccination Reveal Putative Biomarkers Reflecting the Immune Response. Cells, 2022, 11, 1241.	1.8	14
7	Newly Diagnosed Multiple Myeloma Patients with Skeletal-Related Events and Abnormal MRI Pattern Have Poor Survival Outcomes: A Prospective Study on 370 Patients. Journal of Clinical Medicine, 2022, 11, 3088.	1.0	2
8	Comparison of neutralizing antibody responses against SARS-CoV-2 in healthy volunteers who received the BNT162b2 mRNA or the AZD1222 vaccine: Should the second AZD1222 vaccine dose be given earlier?. American Journal of Hematology, 2021, 96, E321-E324.	2.0	17
9	Antibody Response After Initial Vaccination for SARS-CoV-2 in Patients With Amyloidosis. HemaSphere, 2021, 5, e614.	1.2	7
10	Systemic IL-15, IFN- $\beta$ , and IP-10/CXCL10 signature associated with effective immune response to SARS-CoV-2 in BNT162b2 mRNA vaccine recipients. Cell Reports, 2021, 36, 109504.	2.9	137
11	Comparative kinetics of SARS-CoV-2 anti-spike protein RBD IgGs and neutralizing antibodies in convalescent and naïve recipients of the BNT162b2 mRNA vaccine versus COVID-19 patients. BMC Medicine, 2021, 19, 208.	2.3	52
12	The Genomic Landscape of Waldenström Macroglobulinemia Reveals Sustained Germinal Center Activity and Late-Developing Copy Number Aberrations. Blood, 2021, 138, 2394-2394.	0.6	0
13	A Cancer-Related microRNA Signature Shows Biomarker Utility in Multiple Myeloma. International Journal of Molecular Sciences, 2021, 22, 13144.	1.8	13
14	Characterization of a PERK Kinase Inhibitor with Anti-Myeloma Activity. Cancers, 2020, 12, 2864.	1.7	12
15	Anti-SARS-CoV-2 Antibody Responses in Convalescent Plasma Donors Are Increased in Hospitalized Patients; Subanalyses of a Phase 2 Clinical Study. Microorganisms, 2020, 8, 1885.	1.6	39
16	Cell-free DNA analysis for the detection of MYD88 and CXCR4 mutations in IgM monoclonal gammopathies; an update with clinicopathological correlations. American Journal of Hematology, 2020, 95, E148-E150.	2.0	12
17	Integrative analysis of the genomic and transcriptomic landscape of double-refractory multiple myeloma. Blood Advances, 2020, 4, 830-844.	2.5	54
18	A new genetic variant of hereditary apolipoprotein A-I amyloidosis: a case-report followed by discussion of diagnostic challenges and therapeutic options. BMC Medical Genetics, 2019, 20, 23.	2.1	8

#	ARTICLE	IF	CITATIONS
19	Detection of MYD88 and CXCR4 mutations in cell-free DNA of patients with IgM monoclonal gammopathies. <i>Leukemia</i> , 2018, 32, 2617-2625.	3.3	40
20	Semaphorin 4D correlates with increased bone resorption, hypercalcemia, and disease stage in newly diagnosed patients with multiple myeloma. <i>Blood Cancer Journal</i> , 2018, 8, 42.	2.8	29
21	Genetic factors related with early onset of osteonecrosis of the jaw in patients with multiple myeloma under zoledronic acid therapy. <i>Leukemia and Lymphoma</i> , 2017, 58, 2304-2309.	0.6	17
22	Milder degenerative effects of Carfilzomib vs. Bortezomib in the <i>Drosophila</i> model: a link to clinical adverse events. <i>Scientific Reports</i> , 2017, 7, 17802.	1.6	17
23	Discovery and Optimization of a Selective Ligand for the Switch/Sucrose Nonfermenting-Related Bromodomains of Polybromo Protein-1 by the Use of Virtual Screening and Hydration Analysis. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 8787-8803.	2.9	41
24	Characterization of a PERK Kinase Inhibitor with Anti-Myeloma Activity. <i>Blood</i> , 2015, 126, 4188-4188.	0.6	1
25	Genetic Factors Related with Early Onset of Osteonecrosis of the Jaw in Patients with Multiple Myeloma Under Zoledronic Acid Therapy. <i>Blood</i> , 2014, 124, 2115-2115.	0.6	0
26	Translating Findings of Proteasome Inhibitors Effects from the in Vivo <i>Drosophila</i> Experimental Model to Humans: The Paradigm of the Molecular-Cellular Responses to Bortezomib and Carfilzomib. <i>Blood</i> , 2014, 124, 4814-4814.	0.6	0
27	Clinical and genetic factors associated with venous thromboembolism in myeloma patients treated with lenalidomide-based regimens. <i>American Journal of Hematology</i> , 2013, 88, 765-770.	2.0	40
28	Genetic Variations In TLR-4/TIRAP Genes Influence Response To IMiDs-Based Regimens and Conventional Chemotherapy In Patients With Multiple Myeloma. <i>Blood</i> , 2013, 122, 1861-1861.	0.6	0
29	XBP1s levels are implicated in the biology and outcome of myeloma mediating different clinical outcomes to thalidomide-based treatments. <i>Blood</i> , 2010, 116, 250-253.	0.6	107